**ASX ANNOUNCEMENT** **6 November 2025**

# Investor Webinar

**Melbourne, Australia; 6 November 2025:** Cynata Therapeutics Limited (ASX: **"CYP"**, **"Cynata"**, or the **"Company"**), a clinical-stage biotechnology company specialising in cell therapeutics, reminds shareholders that CEO and Managing Director, Dr Kilian Kelly, will host an investor webinar today, Thursday 6 November 2025 at 11:30am AEST.

Attendees are required to register in advance for the webinar using the following link: https://us02web.zoom.us/webinar/register/WN_QlGafabxSbmstpTJtioYGQ

Upon registration, attendees will receive details to access the webinar.

A copy of the presentation to be delivered during the webinar is attached to this announcement.

After the webinar is complete, a recording will be available on the Company's InvestorHub portal. This portal enables shareholders, stakeholders, prospective investors and partners to learn more about the Company's activities and key projects. The Company regularly uploads new content to the hub, including videos, key project news and updates. Shareholders and interested parties can join InvestorHub via the "sign up" button on the Company's website (www.cynata.com).

**-ENDS-**

**Authorised for release by Dr Kilian Kelly, CEO & Managing Director**

***CONTACTS:*** Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com

**About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**

cynata therapeutics

# Investor Webinar: Quarterly Update

6 November 2025

**(ASX:CYP)**

# Important Information

**Summary information**

This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (**CYP**, or **Cynata**) which is current as at 5 November 2025. This Presentation should be read in conjunction with CYP's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (**ASX**), which are available at www.asx.com.au.

**Not an offer**

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

**Not investment advice**

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities.

**Investment risk and past performance**

An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance.

**Financial data**

All financial information in this Presentation is in Australian currency (A$) unless otherwise stated. This Presentation contains historical financial information based on financial information that has been disclosed to the ASX. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding.

**Forward-looking statements**

This Presentation contains certain 'forward-looking statements', which can generally be identified by the use of forward looking words such as 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance', 'potential' and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements.

**Industry and Market data**

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

**Disclaimer**

To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (**Related Persons**) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice.

# Clinical Countdown Begins

**We are approaching a period of rare opportunity for an ASX biotech**

- Entering the most important chapter in Cynata's history
- Expecting two major clinical trial readouts within the next 6-9 months
- Trials are designed to show efficacy of Cymerus™ products in diseases with unmet need
- Building on positive efficacy data from prior studies, with no material safety concerns identified
- Results could transform Cynata's commercial trajectory and valuation

Cynata's MSCs In Storage

# This Quarter Mattered

**Despite limited news the quarter was a foundation-building period**

- Continued progression of Phase 2 (aGvHD) & Phase 3 (Osteoarthritis) clinical trials
- Strengthened relationships with key trial investigators, clinical sites and KOLs
- Ongoing work to support progress towards late-stage development and commercialisation
- Met with advisors, industry partners and ecosystem stakeholders at events / conferences
- Increased engagement and promotion with brokers, funds and investors

## Strong Balance Sheet


1 - As of 30 September 2025; based on cash balance at end of quarter of ~$3.2m plus 2025 FY R&D Tax Incentive rebate of ~$1.7m, received on 5 November 2025.
2 – As announced on 22 August 2025, the Company has entered into an At-the-Market Subscription Agreement ("ATM") with Acuity Capital. The ATM provides Cynata with up to $7,500,000 of standby equity capital over the coming five years, to 31 July 2030.

# Cynata Is At An Inflection Point

- Advancing four clinical programs to address critical treatment gaps
- Company- (and industry-) defining data readouts this financial year
- Manufacturing process established and ready to scale
- Positioned well for global licensing and joint venture deals

## Tightly focused clinical pipeline

| | Phase 1 | Phase 2 | Phase 3 | Market Size | Next Catalyst* |
|---|---|---|---|---|---|
|  **Osteoarthritis** CYP-004 | | | Ongoing | US$11.6bn[3] | Results: Q2 CY 2026 |
|  **Acute Graft vs Host Disease** CYP-001 | ✓ | Ongoing | | US$600m[1] | Results: Q2 CY 2026 |
|  **Kidney Transplantation** CYP-001 | | Ongoing | | US$5.9bn[4] | Cohort 1 Results: Q4 CY 2025 |
|  **Diabetic Foot Ulcers** CYP-006TK | Complete ✓ | | | US$9.6bn[2] | Results Released: Dec 2024 |

1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026)
2. Zion Market Research, 2019 (represents global treatment market in 2025)
3. Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025);
4. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019

* Timing of events is approximate, based on the Company's information as at the date of this presentation, and subject to change. CY = calendar year.

# aGvHD: Phase 2 Trial

- Trial being conducted in Australia, USA, and Europe
- 59 patients randomised so far
- Original target was to randomise 60 patients, to result in at least 56 receiving study treatment
- Target revised to 64 randomised, as 8 patients have withdrawn before receiving study treatment.
- Completion of enrolment anticipated by end CY 2025
- Primary results (after 100 days' follow-up) anticipated **Q2 CY 2026**

# Osteoarthritis: Phase 3 Trial

- Trial being conducted in Australia
- Enrolment and treatment of all 321 patients **complete**
- Final results anticipated **Q2 CY 2026**
- Following advisory meeting with the TGA[2], Cynata is optimistic that positive results could support marketing approval of CYP-004 in Australia

1. Trial being conducted by University of Sydney & funded by National Health and Medical Research Council
2. TGA = (Australian) Therapeutic Goods Administration

# Kidney Transplantation: Phase 1/2 Trial

- Trial being conducted in the Netherlands[1]
- Enrolment and treatment of patients in Cohort 1 (n=3) **complete**
- Results of DSMB[2] review of Cohort 1 are anticipated this quarter (**Q4 CY 2025**)

1. Trial being conducted and funded by Leiden University Medical Center
2. DSMB = Data and Safety Monitoring Board

# The Next 6-9 Months Will Define Cynata

## Upcoming Landmark Readouts

| | Market Size | Next Catalyst* |
|---|---|---|
|  **Osteoarthritis** CYP-004 | US$11.6bn[2] | Phase 3 Results: Q2 CY 2026 (Efficacy & safety) |
|  **Acute Graft vs Host Disease** CYP-001 | US$600m[1] | Phase 2 Results: Q2 CY 2026 (Efficacy & safety) |

## Upcoming Preliminary Readout

| | | |
|---|---|---|
|  **Kidney Transplantation** CYP-001 | US$5.9bn[3] | Cohort 1 Phase 1/2 Results: Q4 CY 2025 |

## Later stage results could become a strategic trigger

**Licensing / Partnering**

- Positive Phase 2 & 3 results can trigger regional or indication-specific deals
- All our indications are attractive licensing targets with clear market needs
- Partnership revenue can help fund future trials without equity dilution

**M&A Potential**

- Compelling data + scalable platform = highly strategic assets
- Strong potential for synergies with other MSC technologies in the market

**Joint Development / Pharma Alliances**

- Shared risk models appeal to global pharma with aligned pipelines
- Allows Cynata to enter new markets with global reach and local execution

All commercial activities referenced are potential future options only. No agreements have been made.

1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026)
2. Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025)
3. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019

# What Our Manufacturing Breakthrough Unlocks

**From scientific first to leadership in MSC medicine.**

1. Only company able to produce clinical-grade MSCs from iPSCs at scale
2. Positions Cynata as the global standard for MSC manufacturing
3. Enables licensing and JV deals for off-the-shelf therapies
4. Eliminates decades-old barrier to scalable MSC commercialisation
5. Fit for mainstream use in multibillion-dollar markets
6. Sustainable competitive edge with strong IP moat

# The Investment Case

Why Cynata?
Why Now?

1

**Solves the MSC manufacturing bottleneck with single-donor scalability**

2

**First mover with no direct peers - only clinical grade iPSC MSC platform at scale**

3

**Lead asset backed by FDA Orphan Drug designation and solid IP protection**

4

**Landmark Phase 2 & 3 readouts expected this financial year**

5

**Fully funded through major clinical milestones**

6

**Trades at a discount to biotech peers despite sector leadership**

# Thank You.


Cynata Therapeutics Limited
Level 3, 100 Cubitt Street
Cremorne
VIC 3121
Australia

+61 (03) 7067 6940
investors@cynata.com
www.cynata.com